Publications by authors named "J M van Rooijen"
Differences in the clinical course and treatment responses in individual patients with advanced renal cell carcinoma (RCC) can largely be explained by the different genomics of this disease. To improve the personalized treatment strategy and survival outcomes for patients with advanced RCC, the genomic make-up in patients with advanced RCC was investigated to identify putative actionable variants and signatures. In this prospective multicenter study (NCT01855477), whole-genome sequencing (WGS) data of locally advanced and metastatic tissue biopsies and matched whole-blood samples were collected from 91 patients with histopathologically confirmed RCC.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the effectiveness and safety of the PD-L1 inhibitor durvalumab in patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors as part of a clinical trial called the Drug Rediscovery Protocol (DRUP).
- A total of 26 patients with various solid tumors, who had no other treatment options left, were treated with durvalumab, showing a clinical benefit in 50% of them, with a 27% objective response rate.
- The results suggested that durvalumab was well-tolerated, and specific genetic markers were linked to patients who did not respond well, indicating potential areas for further research in larger studies.
Introduction: Despite evidence-based guidelines, variation in esophageal cancer care exists in daily practice. Many oncology networks deployed regional agreements to standardize the patient care pathway and reduce unwarranted clinical variation. The aim of this study was to explore the trends in variation of esophageal cancer care between participating hospitals of the Managed Clinical Network (MCN) in the Netherlands.
View Article and Find Full Text PDFBackground: Currently, metastatic hormone-sensitive prostate cancer (mHSPC) patients are often treated with docetaxel chemotherapy at the initiation of hormonal therapy. This treatment is based on the results of two pivotal trials. However, trial populations are not a representative of real-world patient populations.
View Article and Find Full Text PDFBackground: Thyroidectomy is a treatment option in some benign thyroid disorders and the definitive treatment option for thyroid cancer. As postoperative mortality is extremely rare data on postoperative complications and long-term health consequences are important.
Objective: To evaluate the frequencies of short- and long-term complications, and their risk factors in pediatric patients (0-18 years) who underwent a thyroidectomy in a tertiary children's hospital.